Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SGK1 | O00141 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24121832 | 0.80 | PDPK1 (0.35) | PDPK1MAPK1 | |
| SCHEMBL30849114 | 0.80 | GRM4 (0.33) | ALDH1A1GRM4 | |
| SCHEMBL25208146 | 0.80 | GRM4 (0.33) | ALDH1A1GRM4 | |
| SCHEMBL29490926 | 0.77 | GRM4 (0.31) | GRM4 | |
| SCHEMBL30424529 | 0.77 | GRM4 (0.31) | GRM4 | |
| SCHEMBL30316949 | 0.77 | GRM4 (0.31) | SGK1GRM4 | |
| SCHEMBL24283777 | 0.77 | GRM4 (0.31) | GRM4 | |
| SCHEMBL25204873 | 0.77 | GRM4 (0.31) | SGK1GRM4 | |
| SCHEMBL30328027 | 0.73 | GRM4 (0.31) | MEN1KMT2AGRM4 | |
| SCHEMBL23064021 | 0.72 | HCAR2 (0.40) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2021061706-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | ALDH1A1 1971/4885PDPK1 380/4885HSD17B10 1484/4885 |
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885PDPK1 271/4885HSD17B10 2515/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885PDPK1 271/4885HSD17B10 2515/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885PDPK1 271/4885HSD17B10 2515/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | ALDH1A1 3565/4885PDPK1 255/4885HSD17B10 2185/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885PDPK1 271/4885HSD17B10 2515/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | ALDH1A1 3301/4885PDPK1 271/4885HSD17B10 2515/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | ALDH1A1 2433/4885PDPK1 819/4885HSD17B10 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.